BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 26798224)

  • 1. Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma.
    Paik W; Kim HS; Choi CG; Kim SJ
    Korean J Radiol; 2016; 17(1):117-26. PubMed ID: 26798224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas.
    Baek HJ; Kim HS; Kim N; Choi YJ; Kim YJ
    Radiology; 2012 Sep; 264(3):834-43. PubMed ID: 22771885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging.
    Lee EK; Choi SH; Yun TJ; Kang KM; Kim TM; Lee SH; Park CK; Park SH; Kim IH
    Korean J Radiol; 2015; 16(6):1341-8. PubMed ID: 26576125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.
    Zolal A; Juratli TA; Linn J; Podlesek D; Sitoci Ficici KH; Kitzler HH; Schackert G; Sobottka SB; Rieger B; Krex D
    J Neurooncol; 2016 May; 127(3):551-7. PubMed ID: 26830088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
    Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
    J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma.
    Sun MZ; Oh T; Ivan ME; Clark AJ; Safaee M; Sayegh ET; Kaur G; Parsa AT; Bloch O
    J Neurosurg; 2015 May; 122(5):1144-50. PubMed ID: 25768833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spin-echo echo-planar perfusion prior to chemoradiation is a strong independent predictor of progression-free and overall survival in newly diagnosed glioblastoma.
    Akgoz A; Rahman R; You H; Qu J; Hamdan A; Seethamraju RT; Wen PY; Young GS
    J Neurooncol; 2014 Aug; 119(1):111-9. PubMed ID: 24792644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
    Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery.
    Roder C; Bisdas S; Ebner FH; Honegger J; Naegele T; Ernemann U; Tatagiba M
    Eur J Surg Oncol; 2014 Mar; 40(3):297-304. PubMed ID: 24411704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
    Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
    Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
    Rulseh AM; Vymazal J
    J Neurooncol; 2020 Jan; 146(1):157-162. PubMed ID: 31797235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes.
    Villanueva-Meyer JE; Han SJ; Cha S; Butowski NA
    J Neurooncol; 2017 Aug; 134(1):213-219. PubMed ID: 28567589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
    Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
    Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy.
    Kreth FW; Thon N; Simon M; Westphal M; Schackert G; Nikkhah G; Hentschel B; Reifenberger G; Pietsch T; Weller M; Tonn JC;
    Ann Oncol; 2013 Dec; 24(12):3117-23. PubMed ID: 24130262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.
    Bag AK; Cezayirli PC; Davenport JJ; Gaddikeri S; Fathallah-Shaykh HM; Cantor A; Han XS; Nabors LB
    J Neurooncol; 2014 Nov; 120(2):361-70. PubMed ID: 25098699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma.
    Elson A; Bovi J; Siker M; Schultz C; Paulson E
    J Neurooncol; 2015 May; 122(3):549-58. PubMed ID: 25700835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models.
    Kickingereder P; Burth S; Wick A; Götz M; Eidel O; Schlemmer HP; Maier-Hein KH; Wick W; Bendszus M; Radbruch A; Bonekamp D
    Radiology; 2016 Sep; 280(3):880-9. PubMed ID: 27326665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of intraoperative resection control modalities on survival following gross total resection of glioblastoma.
    Neidert MC; Hostettler IC; Burkhardt JK; Mohme M; Held U; Kofmehl R; Eisele G; Woernle CM; Regli L; Bozinov O
    Neurosurg Rev; 2016 Jul; 39(3):401-9. PubMed ID: 26860420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
    Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
    Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.